Zolpidem Normon may be available in the countries listed below.
Zolpidem is reported as an ingredient of Zolpidem Normon in the following countries:
Zolpidem tartrate (a derivative of Zolpidem) is reported as an ingredient of Zolpidem Normon in the following countries:
International Drug Name Search
Generic Name: dantrolene (oral) (DAN troe leen)
Brand Names: Dantrium
Dantrolene is a muscle relaxant.
Dantrolene is used to treat muscle spasticity (stiffness and spasms) caused by conditions such as a spinal cord injury, stroke, cerebral palsy, or multiple sclerosis.
Dantrolene is also used to prevent muscle stiffness and spasms caused by malignant hyperthermia (a rapid rise in body temperature) that can occur during surgery with certain types of anesthesia.
Dantrolene may also be used for other purposes not listed in this medication guide.
Before taking dantrolene, tell your doctor if you have a history of liver disease, a breathing disorder such as COPD, heart disease, or a history of heart attack.
Your doctor may occasionally change your dose to make sure you get the best results from this medication.
If you have any of these other conditions, you may need a dose adjustment or special tests to safely use this medication:
a history of liver disease;
a breathing disorder such as COPD (chronic obstructive pulmonary disease); or
heart disease, or a history of heart attack.
Take this medication exactly as prescribed by your doctor. Do not take it in larger amounts or for longer than recommended. Follow the directions on your prescription label.
Your doctor may occasionally change your dose to make sure you get the best results from this medication.
See also: Dantrium dosage (in more detail)
Take the missed dose as soon as you remember. If it is almost time for your next dose, wait until then to take the medicine and skip the missed dose. Do not take extra medicine to make up the missed dose.
Overdose symptoms may include vomiting, diarrhea, and extreme drowsiness or muscle weakness.
severe diarrhea or constipation;
weak or shallow breathing;
pale skin, easy bruising or bleeding;
trouble swallowing, especially if it causes choking;
nausea, stomach pain, low fever, loss of appetite, dark urine, clay-colored stools, jaundice (yellowing of the skin or eyes);
black, bloody, or tarry stools;
coughing up blood or vomit that looks like coffee grounds;
seizure (black-out or convulsions); or
urinating less than usual or not at all.
Less serious side effects may include:
drowsiness, dizziness, weakness, tired feeling;
mild diarrhea or constipation;
mild nausea, vomiting, stomach pain;
problems with speech, balance, or walking;
headache, confusion, vision problems;
sleep problems (insomnia);
sweating, drooling; or
urinating more than usual.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Tell your doctor about all other medications you use, especially:
birth control pills and other hormones; or
a heart or blood pressure medication such as amlodipine (Norvasc), diltiazem (Tiazac, Cartia, Cardizem), felodipine (Plendil), nicardipine (Cardene), nifedipine (Procardia, Adalat), nimodipine (Nimotop), nisoldipine (Sular), or verapamil (Calan, Covera, Isoptin, Verelan).
This list is not complete and there may be other drugs that can interact with dantrolene. Tell your doctor about all your prescription and over-the-counter medications, vitamins, minerals, herbal products, and drugs prescribed by other doctors. Do not start a new medication without telling your doctor.
See also: Dantrium side effects (in more detail)
Dexalgen may be available in the countries listed below.
Hydroxocobalamin is reported as an ingredient of Dexalgen in the following countries:
International Drug Name Search
Tetraguard may be available in the countries listed below.
In some countries, this medicine may only be approved for veterinary use.
Oxytetracycline magnesiumoxyethylammonium (a derivative of Oxytetracycline) is reported as an ingredient of Tetraguard in the following countries:
International Drug Name Search
Risperidona Asol may be available in the countries listed below.
Risperidone is reported as an ingredient of Risperidona Asol in the following countries:
International Drug Name Search
Generic Name: rivastigmine transdermal (riv a STIG meen)
Brand Names: Exelon
Rivastigmine improves the function of nerve cells in the brain. It works by preventing the breakdown of a chemical called acetylcholine (ah see til KO leen). People with dementia usually have lower levels of this chemical, which is important for the processes of memory, thinking, and reasoning.
Rivastigmine transdermal (skin patch) is used to treat mild to moderate dementia caused by Alzheimer's or Parkinson's disease.
Rivastigmine transdermal may also be used for purposes not listed in this medication guide.
Before using rivastigmine transdermal, tell your doctor if you have liver disease, a heart rhythm disorder such as "sick sinus syndrome" (slow heartbeats), an enlarged prostate, urination problems, a seizure disorder, asthma or allergies, tremors or uncontrolled muscle movements, or a history of stomach ulcer.
If you stop using rivastigmine transdermal for any reason, do not restart the medication without talking to your doctor first. You may need to restart treatment with a lower dose.
If you need surgery, tell the surgeon ahead of time that you are using rivastigmine transdermal.
To make sure you can safely use rivastigmine transdermal, tell your doctor if you have any of these other conditions:
liver disease;
recent weight loss or lack of appetite;
a heart rhythm disorder such as "sick sinus syndrome" (slow heartbeats);
a history of stomach ulcer;
an enlarged prostate or urination problems;
epilepsy or other seizure disorder;
asthma or any allergies; or
tremors (dyskinesia) or uncontrolled muscle movements.
Use exactly as prescribed by your doctor. Do not apply more patches or use them for longer than recommended. Follow the directions on your prescription label.
This medication comes with patient instructions for safe and effective use. Follow these directions carefully. Ask your doctor or pharmacist if you have any questions.
Apply the skin patch to a flat, hairless area of the chest, back, side, or outer side of your upper arm. Press the patch firmly with the palm making sure it sticks firmly, especially around the edges.
Avoid placing the patch where it will be rubbed by tight clothing, or in the folds of your skin. The patch should remain flat on the skin at all times. Take care to avoid accidentally removing the patch while showering or during physical activity.
You will wear the patch for 24 hours and then remove it and put on a new one. Apply the new patch to a different skin area on your back each day. Do not use the same spot again for at least 14 days.
If a patch falls off, apply a new patch and wear it for the rest of the day. Change the patch at your usual time the next day.
After removing a skin patch fold it in half, sticky side in, and throw it away where children and pets cannot get to it.
If you need surgery, tell the surgeon ahead of time that you are using rivastigmine transdermal. You may need to stop using the medicine for a short time.
It may take up to 4 weeks of using this medicine before your symptoms improve. For best results, keep using the patches as directed.
If you stop using rivastigmine transdermal for any reason, do not restart the medication without talking to your doctor first. You may need to restart treatment with a lower dose.
Apply a skin patch as soon as you remember. Or you may wait until the next day to apply a patch and skip the missed dose. Do not use extra patches to make up the missed dose.
Overdose symptoms may include severe nausea, vomiting, diarrhea, slow heartbeat, slow or shallow breathing, or hallucinations.
Do not use any cream, lotion, ointment, oil, or powder on the skin where you plan to apply a skin patch. The patch may not stick well to the skin.
nausea and vomiting, loss of appetite, weight loss;
black or bloody stools, coughing up blood or vomit that looks like blood or coffee grounds;
restless muscle movements in your eyes, tongue, jaw, or neck, tremor (uncontrolled shaking);
sudden numbness or weakness, headache, confusion, problems with vision, speech, or balance;
pale skin, easy bruising or bleeding;
confusion, hallucinations; or
pain or burning when you urinate.
Less serious side effects may include:
diarrhea, stomach pain;
headache, tired feeling;
anxiety, depressed mood;
redness, itching, or swelling where the patch was worn;
dizziness, spinning feeling; or
sleep problems (insomnia).
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Usual Adult Dose for Alzheimer's Disease:
Initial Oral Dose: 1.5 mg orally twice a day with morning and evening meals.
After a minimum of two weeks of treatment, if the initial dosage is well tolerated, it may be increased to 3 mg twice a day. Subsequent increases to 4.5 mg and 6 mg twice a day should be attempted only after a minimum of 2 weeks at the previous dosage. The dosage of rivastigmine shown to be effective in controlled clinical trials is 3 to 6 mg twice a day. There is evidence from the clinical trials that dosages at the higher end of this range may be more beneficial.
Initial Patch Dose: 4.6 mg/24 hours
After a minimum of four weeks of treatment and if well tolerated, the dose of the patch be increased to 9.5 mg/24 hours, which is the recommended effective dose.
Maintenance Patch Dose: Dose increases should occur only after a minimum of four weeks at the previous dose, and only if the previous dose has been well tolerated. The maximum recommended dose is 9.5 mg/ 24 hours. Higher doses confer no appreciable additional benefit, and are associated with significant increase in the incidence of adverse events.
Switching from Capsules or Oral Solution: Patients treated with capsules or oral solution may be switched to patches as follows:
A patient who is on a total daily dose of less than 6 mg of oral rivastigmine can be switched to patch dose of 4.6 mg/24 hours.
A patient who is on a total daily dose of 6 to 12 mg of oral rivastigmine may be directly switched to a patch dose of 9.5 mg/24 hours.
It is recommended to apply the first patch on the day following the last oral dose.
Usual Adult Dose for Parkinson's Disease:
Initial dose: 1.5 mg orally twice a day with morning and evening meals
Subsequently, the dose may be increased to 3 mg orally twice a day and further to 4.5 mg twice a day and 6 mg twice a day (based on tolerability) with a minimum of 4 weeks at each dose.
Initial Patch Dose: 4.6 mg/24 hours
After a minimum of four weeks of treatment and if well tolerated, the dose of the patch be increased to 9.5 mg/24 hours, which is the recommended effective dose.
Maintenance Patch Dose: Dose increases should occur only after a minimum of four weeks at the previous dose, and only if the previous dose has been well tolerated. The maximum recommended dose is 9.5 mg/ 24 hours. Higher doses confer no appreciable additional benefit, and are associated with significant increase in the incidence of adverse events.
Switching from Capsules or Oral Solution: Patients treated with capsules or oral solution may be switched to patches as follows:
A patient who is on a total daily dose of less than 6 mg of oral rivastigmine can be switched to patch dose of 4.6 mg/24 hours.
A patient who is on a total daily dose of 6 to 12 mg of oral rivastigmine may be directly switched to a patch dose of 9.5 mg/24 hours.
It is recommended to apply the first patch on the day following the last oral dose.
The following drugs can interact with rivastigmine transdermal. Tell your doctor if you are using any of these:
atropine (Donnatal, and others), benztropine (Cogentin), dimenhydrinate (Dramamine), methscopolamine (Pamine), or scopolamine (Transderm-Scop);
bronchodilators such as ipratroprium (Atrovent) or tiotropium (Spiriva);
glycopyrrolate (Robinul);
mepenzolate (Cantil);
bladder or urinary medications such as darifenacin (Enablex), flavoxate (Urispas), oxybutynin (Ditropan, Oxytrol), tolterodine (Detrol), or solifenacin (Vesicare);
irritable bowel medications such as dicyclomine (Bentyl), hyoscyamine (Anaspaz, Cystospaz, Levsin, and others), or propantheline (Pro-Banthine);
aspirin or other NSAIDs (non-steroidal anti-inflammatory drugs) such as ibuprofen (Advil, Motrin), naproxen (Aleve, Naprosyn, Naprelan, Treximet), celecoxib (Celebrex), diclofenac (Cataflam, Voltaren), indomethacin (Indocin), meloxicam (Mobic), and others; or
medicines used to treat Parkinson's Disease such as levodopa (Dopar, Larodopa, Sinemet, Atamet, others), bromocriptine (Parlodel, others), pergolide (Permax), pramipexole (Mirapex), or ropinirole (Requip).
This list is not complete and other drugs may interact with rivastigmine transdermal. Tell your doctor about all medications you use. This includes prescription, over-the-counter, vitamin, and herbal products. Do not start a new medication without telling your doctor.
See also: rivastigmine side effects (in more detail)
Crezyme may be available in the countries listed below.
Pancreatin is reported as an ingredient of Crezyme in the following countries:
International Drug Name Search
USAN
0000097-59-6
C4-H6-N4-O3
158
Wound healing agent
Dermatological agent: Antipsoriatic
Urea, (2,5-dioxo-4-imidazolidinyl)-
International Drug Name Search
Glossary
| BAN | British Approved Name |
| DCF | Dénomination Commune Française |
| IS | Inofficial Synonym |
| OS | Official Synonym |
| PH | Pharmacopoeia Name |
| USAN | United States Adopted Name |
Cisplatine Merck may be available in the countries listed below.
Cisplatin is reported as an ingredient of Cisplatine Merck in the following countries:
International Drug Name Search
Propiverin-HCl Stada may be available in the countries listed below.
Propiverine hydrochloride (a derivative of Propiverine) is reported as an ingredient of Propiverin-HCl Stada in the following countries:
International Drug Name Search
Prolift may be available in the countries listed below.
Reboxetine is reported as an ingredient of Prolift in the following countries:
Reboxetine mesilate (a derivative of Reboxetine) is reported as an ingredient of Prolift in the following countries:
International Drug Name Search
Roaccutane may be available in the countries listed below.
UK matches:
Isotretinoin is reported as an ingredient of Roaccutane in the following countries:
International Drug Name Search
Glossary
| SPC | Summary of Product Characteristics (UK) |
Shemol may be available in the countries listed below.
Timolol maleate (a derivative of Timolol) is reported as an ingredient of Shemol in the following countries:
International Drug Name Search
Asamax may be available in the countries listed below.
Mesalazine is reported as an ingredient of Asamax in the following countries:
International Drug Name Search
By-Madol may be available in the countries listed below.
Tramadol hydrochloride (a derivative of Tramadol) is reported as an ingredient of By-Madol in the following countries:
International Drug Name Search
